News by topic

Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

New and experimental HIV treatments news

Show

From To
Treatment-experienced people
Redefining Expanded Access Programs for patients with MDR-HIV

It is time to create a new paradigm to break the vicious cycle of single drug access that has failed these patients.

Published
04 December 2012
From
GMHC Treatment Issues
HIV treatment
New fixed-dose combination pills measure up to Atripla - corrected version*

Several studies, or updates of studies, comparing newer against older drug regimens were presented at the Eleventh International Congress on Drug Therapy in HIV Infection last week.

Published
20 November 2012
By
Gus Cairns
New and experimental HIV treatments
Merck & Co and Gilead highlight new data at international HIV meeting

Data on Isentress (raltegravir), Stribild (elvitegravir 150mg/cobicistat 15 mg/emtricitabine 200mg/tenofovir disoproxil fumarate 300 mg) and Complera (emtricitabine/rilpivirine/tenofovir disoproxil fumarate).

Published
16 November 2012
From
The Pharma Letter
New and experimental HIV treatments
Glaxo-Pfizer HIV Drug Helps Hard-to-Treat Patients

An experimental treatment for HIV developed by GlaxoSmithKline Plc (GSK), Pfizer Inc. (PFE) and Shionogi & Co. (4507) reduced the virus in hard-to-treat patients in a late-stage study, providing further support for a regulatory filing by the end of this year.

Published
14 November 2012
From
Bloomberg
New and experimental HIV treatments
FDA approves new 800mg PREZISTA® (darunavir) tablet

Janssen Therapeutics, Division of Janssen Products, LP announced today the U.S. Food and Drug Administration (FDA) has approved a new 800mg tablet of PREZISTA® (darunavir).

Published
12 November 2012
From
Janssen press release
New and experimental HIV treatments
Is protease inhibitor monotherapy sufficient to keep HIV under control in the brain?

Researchers in Sweden and Switzerland have been conducting clinical trials of PI monotherapy and HIV-related neurological research. Recently, two teams have separately reported that their data strongly suggest that injury to cells within the brain has occurred in some participants when exposed to PI monotherapy. The Swedish team recommends that PI monotherapy be used cautiously until further clinical trials are completed and more detailed information on the brain health of participants becomes available.

Published
02 November 2012
From
CATIE
New and experimental HIV treatments
Gilead: HIV drug meets key Phase 2 trial objective

Gilead Sciences Inc. said a Phase 2 clinical trial evaluating its HIV-1 infection treatment met its primary objective, allowing the company to push forward with its study of the drug. The trial for tenofovir alafenamide fumarate, or TAF, compared a a once-daily single tablet regimen of TAF combined with other drugs against Stribild.

Published
31 October 2012
From
Gilead press release
How HIV causes disease
Groundbreaking Research Discovers Possible New Way To Fight HIV

New research has disocvered how the HIV virus targets memory T-cells or "veterans" instead of naive "virgin" T-cells. This could potentially change how drugs are used to halt the virus. This research finds that HIV exploits the fact that memory T-cells are more mobile; it uses the cytoskeleton, the internal structure of the cell, as a "conveyor belt" to carry it deep within the cell and to the nucleus. The researchers are now looking at whether drugs that reduce cancer cell motility could reduce the "attractiveness" of T-memory cells to HIV.

Published
25 October 2012
From
Medical News Today
New and experimental HIV treatments
Invisible RNAs as Anti-HIV Drug Targets

Scientists say they have visualized, for the first time, fleeting changes in RNA structure that direct biological function through altered cell signalling, and may represent a completely new class of targets for the development of drugs, including those against viral and bacterial pathogens.

Published
10 October 2012
From
Genetic Engineering News
Starting treatment
Thalidomide for HIV-Related IRIS Shows Promise

Thalidomide, a historically controversial drug, may hold potential for people living with HIV who experience immune reconstitution inflammatory syndrome (IRIS) and do not respond favorably and quickly to corticosteroids like prednisone, according to a small series of case reports published online ahead of print by the journal AIDS. 

Published
24 September 2012
From
AIDSMeds
← Prev1...23456...66Next →

Filter by country